Stay updated with breaking news from Repligen Co. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Raymond James & Associates lowered its holdings in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 0.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,911 shares of the biotechnology company’s stock after selling 529 shares during the quarter. Raymond […]
California Public Employees Retirement System trimmed its holdings in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,450 shares of the biotechnology company’s stock after selling 8,870 shares during the period. California Public Employees […]
Skandinaviska Enskilda Banken AB publ bought a new position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 9,679 shares of the biotechnology company’s stock, valued at approximately $1,639,000. Several other hedge funds have also modified […]
Repligen Co. (NASDAQ:RGEN – Get Rating) Director Martin D. Madaus acquired 500 shares of the business’s stock in a transaction dated Monday, May 8th. The stock was acquired at an average cost of $156.18 per share, with a total value of $78,090.00. Following the purchase, the director now directly owns 1,611 shares in the company, […]
Repligen Co. (NASDAQ:RGEN – Get Rating) – Research analysts at SVB Leerink lowered their Q4 2023 earnings per share estimates for Repligen in a note issued to investors on Tuesday, May 2nd. SVB Leerink analyst P. Souda now forecasts that the biotechnology company will post earnings per share of $0.63 for the quarter, down from […]